Core Viewpoint - The company has received the Medical Device Registration Certificate from the National Medical Products Administration for its disposable intracardiac ultrasound imaging catheter, indicating a significant regulatory milestone for the product [1] Product Details - The product is designed for use in medical institutions in conjunction with portable digital color ultrasound diagnostic devices for ultrasound imaging of the heart, major blood vessels, and intracardiac anatomical structures [1] - When used with a three-dimensional cardiac electrophysiology mapping system, the catheter provides catheter positioning information, enhancing procedural accuracy [1] - The catheter features magnetic positioning capabilities, allowing for simultaneous ultrasound imaging and catheter localization, which provides additional intraoperative information to physicians [1]

Core Viewpoint - Tianyi Medical (301097.SZ) announced that its subsidiary, Ningbo Tianyi Pharmaceutical Technology Co., Ltd., has received a Medical Device Registration Certificate from the National Medical Products Administration for its product "Hemodialysis Concentrate" [1] Group 1 - The hemodialysis concentrate consists of two components: A Concentrate (referred to as A Liquid) and B Powder (referred to as B Powder) [1] - A Liquid is composed of sodium chloride, potassium chloride, calcium chloride, magnesium chloride, acetic acid, and dialysis water, while B Powder is made of sodium bicarbonate [1] - A Liquid models are TR-YA3-01 and TR-YA3-02, with specifications of 5L and 10L barrels respectively; B Powder model is TR-FB-LBT1, with a specification of 650g can [1]

Core Viewpoint - The company and its subsidiary Hangzhou Danwei have recently obtained multiple medical device product registration certificates, enhancing their product offerings and market reach [1] Domestic Developments - Hangzhou Danwei's Mycoplasma pneumoniae nucleic acid detection kit (fluorescent PCR method) has been registered, with a validity period until January 18, 2031 [1] International Developments - The company has received registration certificates for several products, including the creatine kinase isoenzyme detection kit, in Brazil and the European Union, with varying validity periods [1] Product Portfolio Enhancement - The recent certifications supplement the company's pneumonia detection product series and improve the layout of time-resolved fluorescence immunochromatography products, expanding the sales regions [1] Sales Performance Outlook - Actual sales performance from these newly registered products cannot be predicted at this time [1]

Core Viewpoint - The company has received a medical device registration certificate for its Immunoglobulin G (IgG) assay kit, which is expected to positively impact its development but will not significantly affect recent production or performance [1] Group 1: Product Development - The product is an IgG assay kit using latex immunoturbidimetry, designed for the quantitative measurement of IgG levels in human urine [1] - This new product enriches the company's biochemical testing product line in the "renal function" category [1] Group 2: Market Impact - The approval of the medical device registration certificate is anticipated to have a positive influence on the company's growth [1] - However, it is noted that there will be no major impact on the company's recent operations and financial performance [1]

Core Viewpoint - The company has received a medical device registration certificate for the 17α-hydroxyprogesterone assay kit, which is significant for diagnosing adrenal cortex diseases [1] Group 1: Product Registration - The product is classified as a Class II medical device and has a validity period until January 18, 2031 [1] - The assay kit is used for the quantitative measurement of 17α-hydroxyprogesterone levels in human serum [1] Group 2: Market Impact - The acquisition of the registration certificate enhances the company's portfolio of electrochemiluminescence assay products, increasing its market competitiveness [1] - The actual sales performance of the product post-launch will depend on market promotion efforts, making the future impact on the company's performance uncertain [1] Group 3: Company Achievements - As of the announcement date, the company and its subsidiaries have obtained 109 medical device registration certificates for electrochemiluminescence assay kits [1]

Core Viewpoint - The company has received a medical device registration certificate for its myoglobin assay kit, which is intended for the quantitative measurement of myoglobin levels in human serum or plasma, aiding in the diagnosis of myocardial infarction [1] Group 1: Product Development - The myoglobin assay kit utilizes a latex immunoturbidimetric method [1] - The approval from the Guangdong Provincial Drug Administration enhances the company's portfolio in the "cardiovascular and myocardial markers" category of biochemical testing products [1] Group 2: Impact on Business - The introduction of this new product is expected to have a positive impact on the company's development [1] - However, it will not significantly affect the company's recent production operations and performance [1]

Core Viewpoint - 乐心医疗 has received II class medical device registration for its blood glucose meter, which is expected to enhance its product competitiveness and expand its blood glucose business [1] Group 1: Company Performance - As of January 19, 2026, 乐心医疗's stock closed at 15.15 yuan, down 0.98% from the previous trading day, with a total market capitalization of 3.312 billion yuan [1] - The stock opened at 15.19 yuan, reached a high of 15.4 yuan, and a low of 14.95 yuan, with a trading volume of 185 million yuan and a turnover rate of 7.5% [1] Group 2: Product Development - The blood glucose meter, based on electrochemical principles, is designed for quantitative detection of whole blood glucose levels, suitable for home patients and healthcare professionals [1] - The model GBZ41-B features Bluetooth functionality, allowing data to be uploaded to a designated app [1] - The acquisition of the registration certificate is a significant advancement for the company's fundraising project, aiding in the implementation of its strategy [1] Group 3: Market Impact - The actual sales performance of the product will be influenced by market promotion efforts, and the future impact on the company's performance remains uncertain [1]

Core Viewpoint - The company, 乐心医疗 (Lixun Medical), has received approval from the Guangdong Provincial Drug Administration for its application regarding the registration of blood glucose monitoring medical devices [1] Group 1 - The company has successfully passed the approval process for its blood glucose meter medical device registration [1]

Core Viewpoint - Tianyi Medical (301097.SZ) has received a medical device registration certificate from the National Medical Products Administration for its product, a disposable continuous renal replacement therapy circuit [1] Group 1: Product Details - The registered product is a complete and integrated system designed for extracorporeal circulation, specifically for continuous renal replacement therapy [1] - The multi-channel design and comprehensive safety accessories of the product are tailored to meet the clinical operational and safety needs in intensive care environments [1] - The product is compatible with the Nikkiso Aquarius blood purification device [1] Group 2: Market Implications - The issuance of the registration certificate signifies the successful extension of the company's product registration, demonstrating ongoing compliance with regulatory requirements [1] - This development is expected to positively impact the company's market competitiveness and expansion [1]

Core Viewpoint - Meikang Bio (300439.SZ) has recently obtained the Medical Device Registration Certificate for in vitro diagnostic reagents from the National Medical Products Administration and Zhejiang Provincial Medical Products Administration, which includes the hepatitis B virus e antibody detection kit and the Golgi protein 73 detection kit [1] Group 1 - The company has received regulatory approval for two diagnostic kits [1] - The approved products utilize chemiluminescent microparticle immunoassay technology [1]